MarketCapExport financials
Immutep Limited (IMMP)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Immutep Limited Cash Flow 2025-2011 | IMMP
Brief overview of Immutep Limited's cash generation
The review uses the five latest available annual reports between 2017 and 2021.
The latest year produced an operating outflow of -17.6 million AUD. A return to positive cash generation is important.
Positive operating cash flow appeared only 0 times out of five; a stable cash profile has not formed.
Cash flow takeaway
Immutep Limited's cash flows remain vulnerable. Negative or unstable generation materially reduces financial flexibility.
Annual Cash Flow Immutep Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-62 M | -34.8 M | -35.4 M | -30.2 M | -17.6 M | -10.8 M | -15.3 M | -7.78 M | -8.51 M | -11.3 M | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in AUD currency
Quarterly Cash Flow Immutep Limited
| 2025-Q4 | 2024-Q4 | 2023-Q4 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|
Quarterly performance
Select metrics to display
All numbers in AUD currency
Cash Flow Statement is one of the three key financial reports of the company Immutep Limited, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Biotechnology sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Aclaris Therapeutics
ACRS
|
$ 3.9 | 8.03 % | $ 478 M |  USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
$ 27.98 | 4.29 % | $ 4.25 B | USA |
 |
Cellectar Biosciences
CLRB
|
$ 1.24 | 7.83 % | $ 3.23 M | USA |
 |
Larimar Therapeutics
LRMR
|
$ 2.4 | 3.23 % | $ 199 M | USA |
 |
Capricor Therapeutics
CAPR
|
$ 8.97 | 4.3 % | $ 417 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
$ 28.5 | 3.04 % | $ 1.33 B | USA |
 |
Aquestive Therapeutics
AQST
|
$ 3.6 | -1.64 % | $ 385 M | USA |
 |
Jaguar Health
JAGX
|
$ 0.4 | -2.16 % | $ 933 K | USA |
 |
Arvinas
ARVN
|
$ 6.41 | -2.14 % | $ 454 M | USA |
 |
Cerus Corporation
CERS
|
$ 2.03 | -4.93 % | $ 387 M | USA |
 |
Beam Therapeutics
BEAM
|
$ 26.43 | 2.15 % | $ 2.61 B | USA |
 |
Fortress Biotech
FBIO
|
$ 1.86 | 0.82 % | $ 51.9 M | USA |
 |
Inhibrx
INBX
|
$ 84.71 | 5.52 % | $ 3.99 B | USA |
 |
Entera Bio Ltd.
ENTX
|
$ 3.16 | 5.69 % | $ 146 M |  Israel |
 |
Legend Biotech Corporation
LEGN
|
$ 23.43 | 3.95 % | $ 8.64 B | USA |
 |
CytomX Therapeutics
CTMX
|
$ 2.19 | 2.1 % | $ 302 M | USA |
 |
Krystal Biotech
KRYS
|
$ 300.7 | 0.15 % | $ 8.7 B | USA |
 |
Kura Oncology
KURA
|
$ 7.15 | 5.15 % | $ 627 M | USA |
 |
Inhibikase Therapeutics
IKT
|
$ 1.5 | 4.17 % | $ 147 M | USA |
 |
Heron Therapeutics
HRTX
|
$ 0.29 | 2.25 % | $ 48.3 M | USA |
 |
Inovio Pharmaceuticals
INO
|
$ 1.22 | -16.21 % | $ 57.2 M | USA |
 |
Corvus Pharmaceuticals
CRVS
|
$ 10.56 | 8.5 % | $ 834 M | USA |
 |
Aytu BioScience
AYTU
|
$ 1.82 | 0.55 % | $ 22.4 M | USA |
 |
Innoviva
INVA
|
$ 19.09 | -0.78 % | $ 1.29 B | USA |
 |
BioCardia
BCDA
|
$ 0.86 | -3.12 % | $ 5.73 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
$ 2.44 | 9.91 % | $ 15.6 B |  Australia |
 |
Certara
CERT
|
$ 12.12 | -0.53 % | $ 1.94 B | USA |
 |
Dyadic International
DYAI
|
$ 0.33 | -2.68 % | $ 11.9 M | USA |
 |
Oramed Pharmaceuticals
ORMP
|
$ 3.86 | -0.77 % | $ 160 M | Israel |
 |
Anika Therapeutics
ANIK
|
$ 14.56 | -24.68 % | $ 209 M | USA |
 |
Aprea Therapeutics
APRE
|
$ 0.53 | 6.6 % | $ 3.47 M | USA |
 |
Galectin Therapeutics
GALT
|
$ 3.13 | 4.86 % | $ 200 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
$ 72.79 | 1.62 % | $ 7.56 B | USA |
 |
Genprex
GNPX
|
$ 2.09 | -0.48 % | $ 1.95 M | USA |
 |
Innate Pharma S.A.
IPHA
|
$ 1.43 | 2.14 % | $ 128 M |  France |
 |
BioMarin Pharmaceutical
BMRN
|
$ 56.03 | -0.16 % | $ 10.7 B | USA |
 |
Matinas BioPharma Holdings
MTNB
|
$ 1.15 | -0.86 % | $ 6.3 M | USA |
 |
Enanta Pharmaceuticals
ENTA
|
$ 10.99 | 9.03 % | $ 234 K | USA |